Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01964989 · ClinicalTrials.gov registry record · Phase 3
Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of Investigational Flu Vaccine Compared to Approved Flu Vaccine in Children.
A Phase 3 study, sponsored by Seqirus.
- Completed
- Registry status
- Phase 3
- Development phase
- 10,644
- Enrollment target
NCT01964989 is a Phase 3 study that has completed, run by Seqirus. The registered enrollment target is 10,644 participants.
The verdict
NCT01964989, a Phase 3 study, has completed, sponsored by Seqirus.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 10,644 participants
- Enrollment target
Study Summary
Safety, Immunogenicity and Efficacy of an Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine Compared to Non-Adjuvanted Comparator Influenza Vaccine in Children ≥6 to \<72 Months of Age. The study was conducted during the 2013/2014 and 2014/2015 northern hemisphere influenza season.
Interventions
- BIOLOGICAL Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)
- BIOLOGICAL Non-adjuvanted Trivalent Influenza Vaccine (TIV) / Quadrivalent Influenza Vaccine (QIV)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10,644 participants |
| Start Date | 2013-11 |
| Est. Completion | 2016-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01964989
The ClinicalTrials.gov registry entry for NCT01964989 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 10,644 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seqirus, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV) is the first listed.
NCT01964989 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01964989 about?
NCT01964989 is a clinical study titled "Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of Investigational Flu Vaccine Compared to Approved Flu Vaccine in Children.". Safety, Immunogenicity and Efficacy of an Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine Compared to Non-Adjuvanted Comparator Influenza Vaccine in Children ≥6 to \<72 Months of Age. The study was conducted during the 2013/2014 and 2014/2015 northern hemisphere influenza season.
What is the current status of trial NCT01964989?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 10,644 participants. The study started on 2013-11. Estimated completion is 2016-08.
What interventions are being tested in trial NCT01964989?
The interventions under investigation include: Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV) (BIOLOGICAL), Non-adjuvanted Trivalent Influenza Vaccine (TIV) / Quadrivalent Influenza Vaccine (QIV) (BIOLOGICAL).
Who is sponsoring clinical trial NCT01964989?
This trial is sponsored by Seqirus, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.